Wells Fargo Initiates Coverage On Bio-Rad Laboratories with Equal-Weight Rating, Announces Price Target of $340
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has initiated coverage on Bio-Rad Laboratories with an Equal-Weight rating and set a price target of $340.

August 27, 2024 | 9:52 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wells Fargo has initiated coverage on Bio-Rad Laboratories with an Equal-Weight rating and a price target of $340, indicating a neutral stance on the stock.
The Equal-Weight rating suggests that Wells Fargo sees Bio-Rad Laboratories as fairly valued at current levels. The price target of $340 provides a specific valuation benchmark, but the neutral rating implies no strong expectation of significant short-term price movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100